Afficher la notice abrégée

Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany

dc.rights.licenseopenen_US
dc.contributor.authorHYERACI, Giulia
dc.contributor.authorGINI, Rosa
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
ORCID: 0000-0002-2568-1928
IDREF: 181595710
dc.contributor.authorIANNONE, Luigi Francesco
dc.contributor.authorBENEMEI, Silvia
dc.contributor.authorLUPI, Chiara
dc.contributor.authorDE CESARIS, Francesco
dc.contributor.authorGEPPETTI, Pierangelo
dc.contributor.authorROBERTO, Giuseppe
dc.date.accessioned2023-02-22T13:52:35Z
dc.date.available2023-02-22T13:52:35Z
dc.date.issued2023-01-27
dc.identifier.issn1526-4610 (Electronic) 0017-8748 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172056
dc.description.abstractEnOBJECTIVE: To describe the pattern of triptan use by gender in Tuscany, Italy, focusing on special user populations in which evidence on triptan safety is still not conclusive. BACKGROUND: Growing evidence supports the role of gender differences in migraine pathophysiology and treatment. However, gender impact on triptan real-word utilization has been poorly investigated. METHODS: A retrospective, descriptive, cohort study was performed using the population-based Administrative Healthcare Database of Tuscany region (Italy). Subjects registered in the database on the January 1 of each year between 2008 and 2018 were identified. New users (NU) of triptans (ATC:N02CC*) were patients with one or more triptan dispensation during the year of interest and none in the past. Age, cardiovascular comorbidities representing an absolute or a possible contraindication to triptan utilization, concomitant serotonergic medications, and pattern of triptan use during 1-year follow-up were described by gender. RESULTS: A total of 86,109 patients who received one or more triptan dispensing were identified. Of 64,672 NU (men = 17,039; women = 47,633), 10.2% (6823/64,672) were aged >65 years, who were mostly women (n = 4613). Among NU, men and women with absolute cardiovascular contraindications were 4.3% (740/17,039) and 2.1% (1022/47,633), respectively, while those concomitantly taking serotonergic medications were 17.2% (267/1549) and 21.9% (949/4330), respectively (949/4330). Regular users (two or more dispensing with ≥3 months between first and last observed dispensing) accounted for 26.4% of women (12,597/47,633) and 19.11% of men (3250/17,039); frequent users (≥15 dosage units/month during ≥3 consecutive months) were overall 0.1% (94/64,672) and 62.0% (58/94) of them concomitantly received serotonergic medications. CONCLUSION: Considering gender differences in triptan use highlighted here, large scale observational studies are warranted to better define what populations are safe to use triptans and whether it is appropriate to tighten or relax certain recommendations on triptan use. In the meantime, any suspected adverse drug reaction observed in the special user populations highlighted in this study should be promptly reported.
dc.language.isoENen_US
dc.subject.enCardiovascular risk
dc.subject.enDrug utilization
dc.subject.enGender differences
dc.subject.enSerotoninergic co-medications
dc.subject.enTriptan frequent users
dc.subject.enTriptans
dc.title.enUtilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany
dc.title.alternativeHeadacheen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/head.14463en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36705316en_US
bordeaux.journalHeadacheen_US
bordeaux.page222-232en_US
bordeaux.volume63en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04000795
hal.version1
hal.date.transferred2023-02-22T13:52:51Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Headache&rft.date=2023-01-27&rft.volume=63&rft.issue=2&rft.spage=222-232&rft.epage=222-232&rft.eissn=1526-4610%20(Electronic)%200017-8748%20(Linking)&rft.issn=1526-4610%20(Electronic)%200017-8748%20(Linking)&rft.au=HYERACI,%20Giulia&GINI,%20Rosa&BEZIN,%20Julien&IANNONE,%20Luigi%20Francesco&BENEMEI,%20Silvia&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée